EUVIMEDEUVIMED entdecken
Open Access

Identifying the potential therapeutic effects of miR‑6516 on muscle disuse atrophy

Woohyeong Jung, Uijin Juang, Suhwan Gwon, Hounggiang Nguyen, Qingzhi Huang, Soohyeon Lee, Beomwoo Lee, Seon-Hwan Kim, Sunyoung Ryu, Jisoo Park, Jongsun Park

Molecular Medicine Reports · 2024

DOI: 10.3892/mmr.2024.13243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Medicine Reports, 2024. Verfasst von Woohyeong Jung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea. Hauptthemen laut MEDLINE: MicroRNAs, Muscular Atrophy, Muscular Disorders, Atrophic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscle atrophy is a debilitating condition with various causes; while aging is one of these causes, reduced engagement in routine muscle‑strengthening activities also markedly contributes to muscle loss. Although extensive research has been conducted on microRNAs (miRNAs/miRs) and their associations with muscle atrophy, the roles played by miRNA precursors remain underexplored. The present study detected the upregulation of the miR‑206 precursor in cell‑free (cf)RNA from the plasma of patients at risk of sarcopenia, and in cfRNAs from the muscles of mice subjected to muscle atrophy. Additionally, a decline in the levels of the miR‑6516 precursor was observed in mice with muscle atrophy. The administration of mimic‑miR‑6516 to mice immobilized due to injury inhibited muscle atrophy by targeting and inhibiting cyclin‑dependent kinase inhibitor 1b (Cdkn1b). Based on these results, the miR‑206 precursor appears to be a potential biomarker of muscle atrophy, whereas miR‑6516 shows promise as a therapeutic target to alleviate muscle deterioration in patients with muscle disuse and atrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsMuscular AtrophyMuscular Disorders, AtrophicAdultAgedAnimalsFemaleHumansMaleMiceMiddle AgedBiomarkersDisease Models, AnimalMuscle, SkeletalSarcopenia

Stichwörter der Autor:innen

Cdkn1bbiomarkermiR‑6516microRNAmuscle atrophyprecursor of miR‑206

Substanzen

BiomarkersMicroRNAs

Autor:innen und Institutionen

  • Department of Pharmacology, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
  • Department of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon 35015, Republic of Korea.
  • Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon 34134, Republic of Korea.

Zitieren

APA

Jung, W., Juang, U., Gwon, S., Nguyen, H., Huang, Q., Lee, S., Lee, B., Kim, S. H., Ryu, S., Park, J., & Park, J. (2024). Identifying the potential therapeutic effects of miR‑6516 on muscle disuse atrophy. Molecular Medicine Reports. https://doi.org/10.3892/mmr.2024.13243

Vancouver

Jung W, Juang U, Gwon S, Nguyen H, Huang Q, Lee S, et al. Identifying the potential therapeutic effects of miR‑6516 on muscle disuse atrophy. Molecular Medicine Reports. 2024. doi:10.3892/mmr.2024.13243

BibTeX
@article{Jung2024,
  author = {Jung, Woohyeong and Juang, Uijin and Gwon, Suhwan and Nguyen, Hounggiang and Huang, Qingzhi and Lee, Soohyeon and Lee, Beomwoo and Kim, Seon-Hwan and Ryu, Sunyoung and Park, Jisoo and Park, Jongsun},
  title = {Identifying the potential therapeutic effects of miR‑6516 on muscle disuse atrophy},
  journal = {Molecular Medicine Reports},
  year = {2024},
  doi = {10.3892/mmr.2024.13243}
}
Kostenlos starten →